Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-6,300
Closed -$177K 113
2026
Q1
$177K Buy
+6,300
New +$168K 0.01% 133
2025
Q4
Sell
-1,300
Closed -$33.1K 170
2025
Q3
$33.1K Buy
+1,300
New +$32.1K ﹤0.01% 115
2023
Q1
Sell
-11,600
Closed -$594K 136
2022
Q4
$594K Sell
11,600
-133,000
-92% -$6.38M 0.07% 35
2022
Q3
$6.33M Buy
144,600
+29,700
+26% +$1.44M 0.52% 22
2022
Q2
$6.02M Sell
114,900
-122,000
-51% -$6.22M 0.44% 21
2022
Q1
$12.3M Buy
236,900
+233,300
+6,481% +$12.1M 0.47% 31
2021
Q4
$212K Sell
3,600
-73,300
-95% -$3.63M 0.05% 7
2021
Q3
$3.31M Buy
76,900
+19,900
+35% +$882K 0.22% 54
2021
Q2
$2.23M Buy
57,000
+43,500
+322% +$1.69M 0.23% 41
2021
Q1
$490K Buy
13,500
+12,400
+1,127% +$440K 0.04% 49
2020
Q4
$40K Buy
+1,100
New +$40.3K ﹤0.01% 133

Other funds holding PFE

QVR's PFE Position: Q2 2026 in Review

QVR sold out of Pfizer (PFE) in Q2 2026, closing a stake of 11,622 shares — an estimated $326K sold.

QVR first reported a position in PFE in Q1 2021 and held it in 8 quarters. The position peaked at $1.25M in Q3 2022. 491 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • QVR reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • QVR sold 11,622 Pfizer shares in Q2 2026, an estimated $326K.
  • QVR first reported a position in Pfizer in Q1 2021 and held it in 8 quarters.
  • QVR's Pfizer position peaked at $1.25M in Q3 2022.
  • 491 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on QVR's 13F filing for Q2 2026.